ArticleAnnals of translational medicine2022
Durable response to afatinib in an advanced lung adenocarcinoma patient with an EGFR L858R/G729A compound mutation: a case report.
Lige Wu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.